<DOC>
	<DOCNO>NCT02554773</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety tolerability ALN-AT3SC male patient moderate severe hemophilia A B .</brief_summary>
	<brief_title>An Open-label Extension Study Investigational Drug , ALN-AT3SC , Patients With Moderate Severe Hemophilia A B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Completed tolerated study drug dose study ALNAT3SC001 Male age ≥18 year Moderate severe , clinically stable hemophilia A B Agree use 1 effective method contraception throughout study participation 1 month administration last dose study drug Willing able comply study requirement provide write informed consent Clinically significant liver disease Patients know human immunodeficiency virus seropositive CD4 count &lt; 200 cells/μL History venous thromboembolism Current serious mental illness , judgment Investigator , may compromise patient safety , ability participate study assessment , study integrity Clinically relevant history presence cardiovascular , respiratory , gastrointestinal , renal , neurological , inflammatory , disease , judgment Investigator , preclude study participation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Hemophilia</keyword>
	<keyword>RNAi therapeutic</keyword>
</DOC>